Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.

This study found that in biopsied skin samples of alopecia areata, a lower anagen/telogen ratio was associated with increased T cell infiltration, and enhancing the PD-1/PD-L1 axis may inhibit CD8+T cell infiltration and improve the condition.

The researchers reviewed multiple studies and found that baricitinib, a JAK inhibitor, generally improved the condition of patients with severe alopecia areata, with minimal side effects.

In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.

This review examines the clinical presentation of alopecia areata in children and compares it to adult-onset cases, noting that data on pediatric cases is scarce and often varies, with reported onset typically between ages 6 and 12.

Hair follicle-derived melanocyte transplant could effectively treat vitiligo by restoring skin color.

This review discusses the complex etiology and pathogenesis of vitiligo, noting challenges in treatment effectiveness and relapse, and reports no new clinical results.

In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.

This review discusses the pathogenesis and new treatments for alopecia areata, highlighting the role of the hair follicle's immune and hormone systems and potential therapies like JAK inhibitors and immunomodulators.

In this case report, a patient with alopecia universalis experienced hair regrowth after clinical islet transplantation, which may indicate the potential impact of immunosuppressive therapy on this autoimmune condition.

A woman's complete hair loss condition improved after recovering from COVID-19.

This study reports a unique case of identical twins experiencing alopecia areata at the same time, suggesting potential environmental triggers for this polygenic autoimmune condition.

This review highlights the need for a deeper understanding of the genetic mechanisms in alopecia areata to develop evidence-based treatments, but it provides no new experimental results.

Regulatory T cells help prevent autoimmunity and have potential for treating autoimmune diseases.

This review discusses the current state of alopecia areata treatments, noting that while recent advances such as Janus Kinase inhibitors show promise, persistent challenges like limited efficacy, safety concerns, and patient compliance highlight the need for innovative drug discovery and development strategies.

This study found that ChatGPT provided fairly accurate answers to common psoriasis-related questions, as rated by medical experts, although it doesn't fully replace professional medical judgment or diagnosis.

This study found that elevated beta-hydroxybutyrate levels may worsen the inflammatory immune response in alopecia areata patients and could indicate a poor prognosis with chronic hair loss.

This study suggests that novel diagnostic, preventive, and treatment approaches for autoimmune diseases like alopecia areata may be developed by identifying hub genes, and highlights the usefulness of machine learning and bioinformatics in finding new disease biomarkers.

This study explored the psychological experiences of Black women with autoimmune alopecia, revealing that cultural significance of hair and social support are crucial factors, and suggesting a need for increased awareness and targeted support from health professionals and communities.

This case report details a patient with Satoyoshi syndrome presenting with uveitis and impending central retinal vein occlusion, a previously undocumented complication, suggesting uveitis as a potential complication of the syndrome.

This study reported that dupilumab, a human monoclonal antibody, induced hair regrowth in patients with alopecia totalis, suggesting its potential as a treatment for this condition.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

In this study, researchers demonstrated that CD4 T cells from skin-draining lymph nodes in mice with alopecia areata can transfer the disease to recipient mice, revealing a critical role for CD4 T cells in disease development and suggesting potential therapeutic targets.

This narrative highlights a study underscoring that vitiligo and alopecia areata are complex autoimmune conditions, often misclassified as cosmetic, which can hinder patients' access to necessary treatments despite their profound impact on quality of life and associated comorbidities.

This study reported that specific inhibition of the classical complement pathway with BIVV009 prevented C3 deposition along the dermal-epidermal junction in bullous pemphigoid, reflecting its potential efficacy.

This report describes two unusual cases of lichen planopilaris in Caucasian patients, detailing features suggestive of folliculotropic mycosis fungoides and an overlap with systemic lupus erythematosus.

This article hypothesizes that thymoma with aplastic anemia may result from abnormal autoimmune CD8⁺ T lymphocytes produced by the thymoma, potentially leading to other cytotoxic T-cell-mediated autoimmune diseases.

In this case report, a 41-year-old male developed myasthenia gravis following alopecia areata, with prednisolone and tacrolimus improving his symptoms; a literature review identified 29 reported cases of this comorbidity, with some showing additional autoimmune diseases, suggesting a shared immunological mechanism.

This review examines the literature on autoimmune hair loss disorders, highlighting the collapse of immune privilege and the potential role of neurogenic stress in this process, but reports no new clinical results.

This review assesses the effectiveness of various alopecia areata treatments and concludes that only contact sensitizers like diphenylcyclopropenone and squaric acid dibutylester have shown efficacy in evidence-based studies, but it reports no new clinical results.